| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| cfz533 | cd40l receptor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Sjogren's Syndrome[MeSHID:D012859] Graves Disease[MeSHID:D006111] Myasthenia Gravis[MeSHID:D009157] Rheumatoid Arthritis[MeSHID:D001172] |
11.57 | phase 2 | unknown |
| cfz533 | cd40l receptor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Sjogren's Syndrome[MeSHID:D012859] Graves Disease[MeSHID:D006111] Myasthenia Gravis[MeSHID:D009157] Rheumatoid Arthritis[MeSHID:D001172] |
11.57 | phase 2 | antibody |
| click here to return to the previous page | ||||||||